Adaptive plasticity in the hippocampus of young mice intermittently exposed to MDMA could be the origin of memory deficits. by Abad, Sonia et al.
1 
 
ADAPTIVE PLASTICITY IN THE HIPPOCAMPUS OF YOUNG MICE INTERMITTENTLY 
EXPOSED TO MDMA COULD BE THE ORIGIN OF MEMORY DEFICITS 
Abad, S.1; Camarasa, J.1; Pubill, D.1; Camins, A.1,2; Escubedo, E1,* 
1 Department of Pharmacology and Therapeutic Chemistry (Pharmacology Section).     
2 Networking Research Center on Neurodegenerative Diseases (CIBERNED). Instituto de 
Salud Carlos III, Spain 
 
* Author for correspondence:  
Elena Escubedo 
Department of Pharmacology and Therapeutic Chemistry, Faculty of Pharmacy, University of 
Barcelona. Avda. Joan XXIII s/n. Barcelona 08028, Spain. 
Tel: +34-934024531 
Fax: +34-934035982 
E-mail: eescubedo@ub.edu 
Concise title: Adaptive plasticity in the hippocampus of young mice exposed to MDMA 
 
 
 
2 
 
ABSTRACT 
(±)3,4-methylenedioxymethamphetamine (MDMA) is a relatively selective dopaminergic 
neurotoxin in mice. This study was designed to evaluate whether MDMA exposure affects 
their recognition memory and hippocampal expression of plasticity markers. Mice were 
administered with increasing doses of MDMA once per week for 8 weeks (three times in one 
day, every 3h) and sacrificed two weeks (2 w) or three months (3 m) later. The treatment did 
not modify hippocampal tryptophan hydroxylase 2, a serotonergic indicator, but induced an 
initial reduction in dopaminergic markers in substantia nigra, which remained stable for at 
least 3 months. In parallel, MDMA produced a decrease in dopamine (DA) levels in the 
striatum at 2 w, which were restored 3 months later, suggesting dopaminergic terminal 
regeneration (sprouting phenomenon). Moreover, recognition memory was assessed using 
the object recognition test. Young (2 w) and mature (3 m) adult mice exhibited impaired 
memory after 24 h but not after just 1 h retention interval.  Two weeks after the treatment, 
animals showed constant levels of CREB but an increase in its phosphorylated form and in c-
Fos expression. BDNF and especially Arc overexpression was sustained and long lasting. 
We cannot rule out the absence of MDMA injury in the hippocampus being due to the 
generation of BDNF. The levels of NMDAR2B, PSD-95 and synaptophysin were unaffected. 
In conclusion, the young mice exposed to MDMA showed increased expression of early key 
markers of plasticity, which sometimes remained for three months, and suggests 
hippocampal maladaptive plasticity that could explain memory deficits evidenced here.  
KEYWORDS:  
MDMA; mice; recognition memory; BDNF; ARC; synaptic plasticity 
Highlights 
 Intermittent repeated MDMA exposure reduces mouse TH-immunoreactivity in the SN 
 MDMA treatment induces a transient decrease in the striatal DA levels 
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 Mice exhibit a delay-dependent memory impairment that last for 3 months 
 The animals show a significant increase in p-CREB, c-Fos, BDNF and Arc expression 
 We suggest that hippocampal maladaptive plasticity explains the memory deficits 
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Introduction 
(±)3,4-methylenedioxymethamphetamine (MDMA: “ecstasy”) is one of the most popular 
recreational psychoactive substances. Repeated MDMA administration at doses that are not 
thought to have any persistent effect on the dopaminergic system [1] produces long-term 
deficits in neurochemical indices of serotonergic function in the rat brain [2]. Conversely, it is 
generally agreed that in mice, high doses of MDMA induce a relatively selective 
dopaminergic terminal injury in the striatum [3, 4] and only transiently disrupts 5-HT 
neurochemistry in the frontal cortex [3, 5], depending on the administration schedule and 
dose [6, 7].  
 
Several studies in rats report acute effects of MDMA on learning and spatial memory 
functions [8–10]. Moreover, impaired memory has been reported 3 months after MDMA 
administration in rats [11].Studies focusing on long-term consequences of MDMA in mouse 
memory are sparse; probably due to the fact that only a few studies have focused on the 
mouse hippocampus as a potential target for the effects induced by MDMA [12–14]. 
Moreover, none of those studies focuses on plasticity markers and memory with either a 
short or a long delay after MDMA exposition.  
 
The importance of such research comes from the fact that MDMA is considered an addictive 
substance. Addictive drugs, including amphetamines, produce forms of structural plasticity 
that can be observed in the nucleus accumbens and prefrontal cortex. This plasticity reflects 
reorganization of patterns of synaptic connectivity [15], involving stable changes in the brain 
that are responsible for addiction, a life-long condition. In addition to the mesolimbic 
dopamine (DA) pathway, the plasticity may affect structures that mediate learned or 
conditioned responses, such as the amygdala, the hippocampus and the cerebral cortex [16]. 
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MDMA in particular has been associated with stable adaptations in the dendritic structures of 
cortico-striatal neurons, based on a large increase in the spine density in both areas [17]. 
Alterations in intracellular messenger pathways, transcription factors and immediate early 
genes seem to be of fundamental importance for the development of plasticity, which is 
associated with addiction and cognition. Moreover, it is known that phospho-CREB (p-CREB) 
regulates the transcription of genes that contain a CRE (cAMP response element) site within 
their regulatory regions. This  upregulation  initiates some of the long-term changes in 
neuronal circuit functions that in turn promote the transcription of many genes, among them 
Arc, c-Fos, and expression of the NMDA receptor NR1 subunits NR1 and NR2. c-Fos is an 
immediate-early gene (IEG). Its expression by individual neurons can be used as a marker of 
cell activation. Arc (the activity-regulated cytoskeleton-associated gene) is also an IEG which 
is translated to a cytosolic protein involved in the mechanism of synaptic plasticity associated 
with long-term potentiation (LTP) and learning [18]. Expression of Arc mRNA and/or protein 
is increased by neuronal excitation induced by electrical stimulation or by activation of 
glutamatergic, dopaminergic or serotonergic receptors [19–21]. 
 
Another DA-dependent change, strongly associated with drug-induced neuroplasticity, is 
activation of the brain-derived neurotrophic factor (BDNF) expression. BDNF belongs to the 
class of psychostimulant-regulated IEGs [22]. It is well known that BDNF promotes forms of 
excitatory synaptic plasticity, such as early- and late-phase LTP, and also promotes dendritic 
spine formation [23]. Until now, there were no studies of the impact of MDMA on the 
expression of this neurotrophin in the hippocampus of mice, which could provide useful 
information regarding the plasticity developed by the amphetamine derivative. 
 
The effects of MDMA on learning and memory depend on the drug schedule and on the age 
at which the drug is administered [24]. Although a great deal of research has been devoted 
to elucidating the molecular mechanisms responsible for the cognitive deficits induced by 
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MDMA, to date not a single molecule or pathway has been identified. In the present paper 
we focus on MDMA exposure in young mice and its consequences for the young and mature 
adult brain. We attempt to simulate the pattern of human recreational consumption of MDMA 
through the dosage schedule we apply. We use mice, not rats, because this treatment 
schedule seems more likely to produce behavioral deficits in mice without inducing 
hippocampal toxicity. 
Therefore, this study was designed to evaluate whether repetitive and intermittent MDMA 
exposure affects recognition memory and the expression of markers related with this 
cognitive process in a short period after ecstasy exposure. We also aimed to determine 
whether any such changes remain and become chronic, and to identify the type and nature 
of the factors that are mainly responsible for the impact of MDMA on recognition memory. 
MATERIALS AND METHODS 
Animals 
Adolescent male C57BL/6 mice (4-5 weeks old at the beginning of the experiment) (Charles 
River Laboratories, France) were kept under controlled temperature, humidity and light 
conditions with food and water provided ad libitum. They were treated according to European 
Community Council Directive 86/ 609EEC and the procedure registered at the Department 
d’Agricultura, Ramaderia i Pesca of the Generalitat de Catalunya.  
 
Drug treatment 
To model recreational MDMA use, we considered appropriate to simulate the widespread 
practice of “boosting” (taking supplemental doses over time in order to maintain the drug’s 
effect)  [25] MDMA was administered three times in a day, every 3h, once a week for eight 
weeks. The treatment schedule started with a standard dose of MDMA (5 mg/kg) or saline (5 
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ml/kg) [26] and drug increased over the treatment period (up to 10 mg/kg) imitating the 
classic consumption of a reinforcing compound. Accordingly, the doses were: 5 mg/kg (two 
weeks), 7.5 mg/kg (the following three weeks) and 10 mg/kg (the last three weeks). Taking 
into account that the neurotoxic dose in mice is 25 mg/kg, three times in a day, every 3h 
(Colado et al. 2001), the highest dose selected was 10mg/kg. Exposition was at high ambient 
temperature (26ºC) as described elsewhere [27]. After the end of the treatment (ATET), mice 
were killed at two different time points: two weeks ATET (3.5 months old, n=31) and three 
months ATET (6 months old, n=36). At 3-6 months of age, mice have completed their 
development, but are not affected by senescence yet; we referred to them as young (3.5 
months old) and mature (6 months old) adults. 
Therefore, in the present study, four groups were considered: 
 Saline treated mice, killed two weeks ATET: Saline 2w 
 MDMA treated mice, killed two weeks ATET: MDMA 2w 
 Saline treated mice, killed 3 months ATET: Saline 3m 
 MDMA treated mice, killed 3 months ATET: MDMA 3m 
 
Object recognition test 
One week before death, the recognition memory of the animals was tested using the object 
recognition test (ORT). The test consisted of a familiarization session (three consecutive 
days) in which mice explored an arena (a circular area measuring 40 cm diameter) without 
objects for 10 min. During the first familiarization session, the animals were monitored to 
assess locomotor activity (Smart 3; Panlab SL, Barcelona, Spain). On the 4th day, the mice 
were trained with two identical objects, (two objects “A”; 10 min). Novel object recognition 
was tested 1 h and 24 h after the training session, when mice were exposed to the familiar 
object A and a novel object B (1 h) or C (24 h) for 10 min. The time spent by the mice at each 
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of the objects was measured in seconds. Exploration of the objects was defined as sniffing, 
touching and having moving vibrissae whilst directing the nose towards the object at a 
distance of less than 1 cm. The data were expressed as measures of discrimination between 
the new and familiar object, thus correcting the difference in the exploratory time of each 
object by the total exploration time. 
Tyrosine hydroxylase (TH) - positive neurons in substantia nigra (SN) 
Mice were anaesthetized by i.p. injection of ketamine (100 mg/kg) plus xylazine (10 mg/kg) 
and were perfused with 4% paraformaldehyde in 0.1 M phosphate buffer, after which the 
brains were removed. Coronal sections of 30 μm were obtained. Free-floating sections were 
rinsed in 0.1 M phosphate buffer, pH 7.2 and preincubated in a blocking solution (10% fetal 
bovine serum (FBS), 0.2 mol/l of glycine, Triton X-100 0.2% in 0.2% PBS-gelatin). Then, the 
sections were incubated for 48h at 4 °C with mouse anti-tyrosine hydroxylase antibody 
(1:200 BD Biosciencies). After that, the sections were incubated with Alexa Fluor 488 goat 
anti-mouse secondary antibody (1:200; Sigma-Aldrich) for 2 h at room temperature. Finally, 
the slices were mounted on glass slides using Fluoromount (EMS). To quantify the total 
number of TH-positive neurons in the SN, unbiased counting frame was positioned on each 
photomicrograph taken at a magnification of 10x, according to the atlas of [28].  TH-neurons 
were counted in both hemispheres using the Image J software, and the density (cells/area) 
was calculated in relation to the area delimited by the frame. 
 
Measurement of neurotransmitters 
For analysis of neurotransmitter levels, the mice were killed by cervical dislocation and 
decapitation, the brains rapidly removed and the striatum dissected out on ice. Samples were 
prepared by sonication in 10 volumes of 0.1M perchloric acid, centrifuged for 30 min at 
12,000 × g after which 40 μl of filtered supernatant was injected into HPLC system equipped 
with a Waters 2465 electrochemical detector set to a potential +0.70 V, and a column Nova 
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Pack C18 4µm 3.90 x 150 mm (Waters, Milford, MA). The mobile phase consisted of purified 
water with 10% methanol, 1.92 mM 1-octanesulfonic acid, 0.1 mM EDTA and 10 mM 
phosphoric acid. Column temperature was set at 37 °C and a flow rate of 1 ml/min. The 
retention times for norepinephrine (NE), 3,4-dihydroxyphenylacetic acid  (DOPAC), 5-
hydroxyindoleacetic acid (5-HIAA), DA, homovanillic acid  (HVA) and serotonin (5-HT) were 
2.74, 4.46, 6.95, 8.13, 11.24 and 20.66 min, respectively. 
Hippocampal lysate preparation 
The hippocampus was quickly dissected out, frozen and stored at −80 °C until use. When 
required, tissue samples were thawed and homogenated at 4 °C in lysis buffer (Tris-HCl 
20mM, NaCl 137 mM, Nonidet P40 1%, EDTA 2mM, 4.5 μg/μl of aprotinin, 0.1 mM of 
phenylmethylsulfonyl fluoride, 1 mM of sodium orthovanadate, and phosphatase inhibitor 
cocktail 1 (Sigma-Aldrich, St.Louis, MO, USA), lysated samples were mixted in an orbital for 
2 h at 4 °C. The protein samples were then centrifuged at 15,000 xg for 30 minutes. The 
supernatant was recovered and protein content was determined using the Bio-Rad Protein 
Reagent. 
 
Western blotting and immunodetection 
Western blotting (WB) and immunodetection protocol was used to determine the proteins 
levels as described (Pedrós et al., 2014). Primary antibodies are detailed in supplementary 
material. All results are normalized to GAPDH or Actine, unless stated otherwise.  
 
RNA extraction and quantification 
Total RNA was isolated from the hippocampus of mice, using the RNeasy Lipid Tissue Mini 
Kit, according to manufacturer's protocol (Qiagen). RNA pellet was reconstituted in RNAse-
free water, with the RNA integrity determined by Agilent 2100 Bioanalyzer. 
Quantitative RT-PCR  
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First-strand cDNA was reverse transcribed from 1 μg of total RNA from the hippocampus, 
using the High Capacity cDNA Reverse Transcription kit, according to manufacturer's 
protocol (Applied Biosystems). Equal amounts of cDNA of each individual animal were 
subsequently used for qRT-PCR, and each sample was analyzed in duplicate for each gene. 
The PCR reaction contained 15 ng of reverse-transcribed RNA, 2 x IQTM 2SYBRGreen 
Supermix (BioRad, Barcelona, Spain) and 100 nM of each primer.  The PCR assays were 
performed on a StepOnePlus Real Time PCR system (Applied Biosystems), and normalized 
to the average transcription levels of actin, using the delta–delta Ct method [30]. Primer 
Express Software (Applied Biosystems, Foster City, CA) was used to design the primers 
(supplementary material). 
 
Statistical analysis 
Unless otherwise indicated, we used Student’s t-test for comparing the means of two 
treatments (saline or MDMA). All data are presented as mean ± SEM, and the P values less 
than 0.05 were considered as significant. 
 
RESULTS 
Object Recognition test 
On the first day of the familiarization of the ORT, locomotor activity was registered. Student’s 
t-test for distance travelled and locomotor speed showed a significant effect of treatment 
when assayed short time after finishing drug exposure (2w) (distance: 3081.3 ± 160.5 cm 
saline vs 2604.0 ± 132.9 cm MDMA, p <0.05; speed: 5.14 ± 0.24 cm/s saline vs 4.45 ± 0.23 
cm/s MDMA, p <0.05; n=26). This effect disappeared three months after finishing exposure. 
Memory results were analyzed using two-way ANOVA and post-hoc comparisons by Tukey’s 
procedure, as we wanted to assess the effect of two variables: treatment and delay time. 
Both young and mature adult mice previously exposed to MDMA exhibited impaired object 
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recognition memory, measured as reduced novel preference, after a retention interval of 24 h 
but not after just 1 h. Statistical analysis revealed a significant effect of delay time (2w F1,24 = 
83.78, p <0.001, n=26; 3m: F1,21 = 33.23, p <0.001, n=23) and of the interaction treatment x 
delay time (2w: F1,24 = 4.27, p <0.05, n=26; 3m: F1,21 = 60.95, p <0.001, n=23) (see Fig. 1 A 
and B). These results indicate a delay-dependent deleterious effect of the drug on memory. 
As glucocorticoids impair performance of spatial memory [31], we determined the effect of 
our chronic MDMA regimen on this receptor protein in this area. Neither, the 2w group nor 
the 3m group showed any effect of MDMA exposure (2w: 100 ± 7.90% saline vs 91.88 ± 
9.46% MDMA, n=7, n.s.; 3m: 100 ± 11.76% saline vs 120.96 ± 15.47% MDMA, n=7, n.s.) 
Effects of MDMA on neuronal injury markers 
To assess the neurotoxicity we measured neurotransmitter levels in striatum, also counting 
TH-positive cells in SN. To confirm that the treatment did not damage serotonergic terminals 
in the hippocampus, we also evaluated tryptophan-hydroxylase 2 (TPH2), a marker of 5-HT 
terminals. 
Two weeks after the treatment, MDMA exposure caused a significant decrease of striatal DA 
levels (42.1 ± 4.1 nmol/g wet tissue (wt) saline vs 24.8 ± 4.7 nmol/g wt MDMA, n=8 , 
p=0.057) and its main metabolite, DOPAC (14.3 ± 1.0 nmol/g wt saline vs 9.31 ± 0.98 nmol/g 
wt MDMA, n=8, p<0.05), without changing norepinephrine (0.66 ± 0.07 nmol/g wt saline vs 
0.67 ± 0.19 nmol/g wt MDMA, n=8) or 5-HT levels (1.78 ± 0.37 nmol/g wt saline vs 1.77 ± 
0.33 nmol/g wt MDMA, n=8). In parallel, we found a slight MDMA-induced decrease in the 
number of TH-positive neurons in SN (0.26 ± 0.02 positive cells/area saline vs 0.20 ± 0.01 
positive cells/area MDMA, n=12, p<0.05)(Fig. 2). However, no changes were observed for 
TPH2 expression in the hippocampus (100 ± 9.67% saline, 102.54 ± 7.98 % MDMA, n=7). 
When the same parameters were evaluated 3 months ATET, the levels of DA (37.20 ± 2.65 
saline vs 37.70 ± 6.96 MDMA, n=15) and DOPAC (14.48 ± 1.16 saline vs 12.83 ± 1.34 
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MDMA, n=15) were restored in mice exposed to MDMA. As expected, the MDMA effect on 
TH-positive cells in the SN was maintained (0.23 ± 0.01 positive cells/area saline vs 0.18 ± 
0.01 positive cells/area MDMA, n=8, p<.0.05)(Fig. 3) and no changes in TPH2 expression in 
hippocampus were found (100 ± 13.54% saline, 92.18 ± 8.90% MDMA, n=8).  
Effects of MDMA on plasticity markers (P-CREB/CREB) in the hippocampus  
Two weeks after the chronic administration of MDMA, no changes in the total level of CREB 
protein were detected (100 ± 21.37% saline, 97.35 ± 8.57% MDMA, n=9), but an increase in 
its phosporylated form was observed (100 ± 21.37% saline, 165.8 ± 14.62% MDMA; p<0.05). 
As expected, this increase disappeared 3 months after the last dose of the drug (100 ± 
13.95% saline, 89.95 ± 15.72% MDMA, n.s., n= 8) (Fig. 4). 
Early genes/proteins  
We performed PCR and WB assays to determine changes in genes or proteins strongly 
associated with neuroplasticity [22]. Of the CREB-regulated genes, we chose Arc and c-Fos. 
Results showed that both c-Fos mRNA and c-FOS protein in the hippocampus were 
significantly induced by MDMA shortly ATET (mRNA: 100 ± 23.77% saline n=4; 391.1 ± 
46.8% MDMA, n=9, p<0.01) (protein: 100 ± 7.92% saline, 144.0 ± 8.7% MDMA, n=8, 
p<0.01), but returned to basal values when assayed 3 months ATET (Fig. 5; mRNA: 100 ± 
12.24% saline, 117.1 ± 17.17% MDMA, n.s., n=9, protein: 100 ± 16.68% saline, 96.74 ± 
16.68% MDMA, n.s., n=9). The overexpression of c-Fos mRNA and c-FOS protein that lasts 
two weeks indicates a very strong signal during drug exposure. 
Regarding ARC, repeated administration of MDMA to C57BL/6 mice induced significant 
expression of Arc mRNA (100 ± 11.72% saline, 190.2 ± 22.47% MDMA, p<0.05, n= 9) and 
ARC protein (100 ± 5.96% saline, 126 ± 4.61% MDMA, p<0.05, n=8) when assayed 2 weeks 
ATET (Fig. 6A and B). Surprisingly, the overexpression of this gene was sustained and long 
lasting (100 ± 11.17% saline, 163.7 ± 20.67% MDMA, p<0.05, n=9), as shown in MDMA-
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treated mice, 3 months ATET. Nevertheless, no changes were found in ARC protein levels 
(100 ± 4.43% saline, 114.0 ± 11.32% MDMA, n.s., n=7) in mature adult mice (Fig. 6C and D). 
 
BDNF 
Despite of in the present study MDMA did not modify 5-HT parameters in hippocampus, we 
sought to measure its effect on the expression of BDNF, as our group reported increased 
hippocampal BDNF levels depending on cognitive training in rats exposed to MDMA [27]. 
Figure 7 summarizes the effects of MDMA on BDNF levels. A significant increase in BDNF 
mRNA transcript expression was found shortly after drug withdrawal (100 ± 8.01% saline, 
133.6 ± 7.07% MDMA, p<0.05, n=10). Likewise, MDMA-treated animals showed a slight 
increase in BDNF protein levels, although it did not reach statistical significance (100 ± 
10.06% saline, 126.8 ± 10.19% MDMA, n.s., n=8) 
In mature adult mice (3 months ATET), a delayed expression of BDNF protein was observed 
in MDMA-trated animals (100 ± 5.57% saline, 138.35 ± 11.08 MDMA, p<0.05 n=9), although 
mRNA showed non-significant changes (100 ± 11.61% saline, 124.2 ± 11.08% MDMA, n.s., 
n=10). The changes in BDNF expression related with the amphetamine derivative exposure 
are thus independent of the impact of MDMA on hippocampal 5-HT neurochemistry, absent 
from our study. 
Regulation of synaptic plasticity-related proteins 
Finally, other CREB-regulated genes are those encoding glutamate receptors. Synaptic 
plasticity associated with addiction and cognition relies on the normal integration of 
glutamate receptors at the post-synaptic density (PSD). Therefore, we studied the effects of 
MDMA exposure in the levels of four synaptic proteins: PSD-95, NR1, NR2B and 
synaptophysin (2w n=7-9, 3m n=8-11). 
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The effects of the assayed MDMA schedule on these proteins are shown in Fig. 8, and are 
presented as relative protein expression. Although an apparent decrease was observed for 
NR1 expression in both young and mature adults, statistical significance was not reached 
(2w: 100 ± 24.18% saline, 71.91 ± 8.52% MDMA, n.s., n= 7; 3m: 100 ± 27.83% saline, 62.55 
± 12.70% MDMA, p=0.2835, n=10) (Fig 8A and E). Moreover, MDMA failed to induce any 
change in NR2B expression (Fig 8B and F).  
Studies have shown that interactions between the PSD-95 protein and NMDA receptors 
located at the spine tip may also regulate dendritic spine morphology. Thus, we analyzed the 
expression of this protein in the hippocampus of the treated animals. According to our results 
with NR2B, MDMA did not significantly modify the levels of this scaffolding protein (Fig 8C 
and G)(2w: 100 ± 15.24% saline, 71.28 ± 6.11% MDMA, n.s., n= 8; 3m: 100 ± 5.58% saline, 
86.52 ± 6.42% MDMA, n.s., n=9).  
 
Finally, to explore the relationship between the cognitive changes observed in MDMA-treated 
mice and synaptic modifications, we studied the effect of a recent or a long earlier exposure 
in synaptophysin. Once again, our results revealed no relationship in this sense (Fig. 8D and 
H)(2w: 100 ± 14.67% saline, 96.45 ± 16.62% MDMA, n.s., n= 9; 3m: 100 ± 4.79% saline, 
108.67 ± 14.34% MDMA, n.s., n=8) 
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DISCUSSION 
MDMA is an amphetamine derivative that acts as a psychostimulant by increasing 
catecholamine concentration in synapses. In comparison with methamphetamine, MDMA 
has enhanced potency for 5-HT release and reduced potency for DA release [32]. It also acts 
as an agonist of 5-HT2A receptors [33] and, at high doses, as a 5-HT or DA neurotoxin in 
non-human primates, rats and mice, often associated with depletion of 5-HT or DA terminal 
markers [2].  
It is well established that MDMA has a different pharmacology in mouse compared to rat. In 
contrast to its selective 5-HT neurotoxicity in rats, after a binge schedule in mice (20-30 
mg/kg, t.i.d, 3 h intervals), it is a relatively selective DA neurotoxin without long-lasting effects 
on the 5-HT content. Long-term studies in rats demonstrated that after MDMA-induced 
neurotoxicity, significant (even complete) recovery may occur from 8 weeks to a whole year 
[34]. Nevertheless, other studies have shown incomplete recovery in certain brain areas or in 
particular animals after 12-18 months post-treatment [35, 36]. Another important finding from 
those time course studies in rats was the late appearance of a serotonergic hyperinnervation 
of certain subcortical brain areas, a phenomenon thought to reflect axonal/terminal sprouting 
following synaptic loss. 
In the present study, we applied a dosage schedule that imitated classic weekend 
recreational use of MDMA. The highest dose used was notably lower than the dose 
established as toxic in binge regimens [6], but we used a more extended treatment. Costa et 
al. [37] also used a prolonged and intermittent exposure (10 mg/kg two times in a day, twice 
per week during 9 weeks); nevertheless, we thought that once per week and administering 
increasing doses simulates better the pattern of consumption in adolescents. This treatment 
produced an initial reduction in TH-immunoreactivity in the SN, which agreed with the results 
of Costa et al. There were no previous reports of longer-term effects of MDMA on mice, but 
our results here indicate an irreversible effect on dopaminergic neurons in SN or, 
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alternatively, suggest that recovery from dopaminergic damage in mice takes more than 
three months. 
In the striatum, neurotransmitter analysis revealed initial major decrements in DA levels, 
which recovered three months later. This suggests an increase in catecholamine synthesis or 
a compensatory DA axonal sprouting and branching after synaptic loss; or both. Acute 
activation of striatal dopamine synthesis after MDMA could be a compensatory response to 
the carrier-mediated efflux of transmitter [38]. Regarding dopaminergic terminal regeneration 
(sprouting), it was reported in mice 30 days after MDMA exposure [39], and involves 
plasticity events such as reactive synaptogenesis and rerouting of axons to unusual 
locations. In parallel, MDMA-exposed mice significantly reduced the distance travelled and 
speed when assayed shortly after finishing the treatment. These results agree with the 
reduction of DA neurons in SN and with DA depletion in the striatum; and this depressant 
effect disappeared three months later, correlating with the restoration of striatal DA levels. 
In contrast, analysis of the hippocampus collected in 2w and 3m groups yielded no changes 
in the serotonergic marker (TPH2). In the same groups, previously to sacrifice, recognition 
memory was tested using the ORT. When this task was tested after a short retention interval 
(1h), the MDMA-treated mice performed similarly to control animals. However, when memory 
was tested after a long retention interval (24h), for which a key role of the hippocampus has 
been reported, the MDMA group showed a very significant deficit, which was maintained for 
a prolonged time ATET. We ruled out changes in the glucocorticoid receptor as the origin of 
these deficits. These results indicate a delay-dependent deleterious effect of the drug on 
recognition memory, and that the hippocampus is the structure mainly responsible. The 
hippocampus is involved in object recognition memory regardless of retention interval, but 
parahippocampal structures (e.g., perirhinal cortex) are sufficient to support object 
recognition memory over short retention intervals [40].  
17 
 
On the other hand, it has been suggested that structural plasticity associated with exposure 
to drugs of abuse reflects a reorganization of the patterns of synaptic connectivity which 
contributes to some of the persistent effects associated with drug use, including addiction. 
Exposure to amphetamine, cocaine, nicotine or morphine produces persistent changes in the 
structure of dendrites and dendritic spines on neurons in some brain regions, such as those 
associated with incentive motivation, reward and judgment [15]. Furthermore, persistent 
changes, such as those associated with learning and memory, are thought to be due to the 
reorganization of synaptic connections in brain circuits. Therefore MDMA, which induces 
anomalous neuroplasticity as a consequence of its addictive properties [41], could affect 
memory processes. This only could be possible if the plasticity changes are present in brain 
structures related to memory, such as hippocampus. Following rat developmental MDMA 
exposure, Williams et al. [42] found neuronal cytoarchitectural changes, which are long-
lasting and are in regions consistent with the learning and memory deficits observed in such 
animals. Eight weeks after chronic administration of MDMA to rats, van Nieuwenhuijzen et al. 
[43] reported residual changes in hippocampal proteins implicated in learning-related 
neuroplasticity, and our group reported increased hippocampal BDNF levels and an effect on 
spine density depending on cognitive training [27]. However, previously there were no data 
on the effects on mice, where the consequences of MDMA are known to be different. 
The cAMP response element-binding protein binds to CRE sites as a dimer and only 
activates transcription when both subunits are phosphorylated at their Ser133 residue (p-
CREB). As CREB can be phosphorylated at Ser133 by protein kinase A (PKA), p-CREB can 
be detected after DA type1 receptor stimulation by classical psychostimulants. P-CREB may 
initiate some long-term changes in neuronal circuit functions, thereby promoting the 
transcription of many genes, among them Arc, c-Fos, NR1 and NR2B. Therefore, CREB may 
be a universal modulator of processes required for memory formation [44]. Mice exposed to 
the assayed MDMA schedule showed constant levels of CREB but an increase in its 
phosphorylated form. It is worth stressing that these results were obtained in animals whose 
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MDMA exposure finished 2 weeks previously, indicating an important phosphorylation 
stimulus. This was confirmed by measuring c-Fos, a marker of cell activation that behaves 
similarly to p-CREB, which increased shortly after treatment but had then reverted 3 months 
ATET.  
Activity-regulated gene 3.1 (Arg3.1), also known as Arc, is an IEG that is regulated by BDNF- 
and CREB-dependent signaling [45, 46]. Arc protein acts as a stabilization factor for 
filamentous-actin, which results in the regulation of dendritic spine morphology [47, 48]. Arc 
could be considered a key regulator of protein synthesis-dependent forms of synaptic 
plasticity, which are thought to underlie memory storage [49]. In rats, single or repeated 
cocaine treatment, as well as long-term abstinence (48 days) following drug administration, 
all increase Arc expression [50–52], although it is associated, at the same time, with 
alterations in the finely tuned mechanisms that regulate Arc degradation [52]. In our 
experiments, MDMA increased Arc transcript and protein expression after two weeks of 
withdrawal, which was also evident, although reduced, after 3 months of withdrawal. These 
results indicate an intense effect of MDMA on synaptic plasticity particularly intense in the 
early stages of withdrawal which fades with time. 
In the same way, we assayed the effects of MDMA on BDNF. The mRNA related to BDNF 
gene and to that of Arc are induced by cellular activity and transported into dendrites, thereby 
promoting plasticity [22]. The changes in BDNF accumulate and rise with increasing periods 
of abstinence [53]. Martínez-Turrillas et al. [54] studied the effects of an acute administration 
of MDMA to rats. They found that after MDMA, BDNF mRNA levels were increased in frontal 
cortex, but reduced in hippocampus after 48 h, in spite of the marked increase at this time 
point in the levels of the transcription factor pCREB. Those authors attributed this variation to 
the high vulnerability of the rat hippocampus to the neurotoxic effects of the amphetamine. 
However, because hippocampus serotonergic neurotransmission is not affected by MDMA in 
mice, the consequences for BDNF levels are probably different. In neurons, the expression 
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of BDNF mRNA is enhanced when the AMPA-type glutamate receptor is activated [55, 56], 
and requires an increase in intracellular calcium concentrations [57, 58]. We found [59] that 
treatment with MDMA significantly disrupted calcium homeostasis, favoring glutamate 
release in the hippocampus. These results allowed us to speculate about a possible effect of 
MDMA on BDNF expression. Indeed, in this area, we observed that few days after treatment, 
BDNF mRNA levels were increased with no significant effects at protein levels. Conversely, 
BDNF mRNA levels were not affected 3 months after exposure, while it significantly 
increased protein levels. This suggests that prolonged exposure to MDMA differently affects 
BDNF transcription and translation. It is known [60] that after an appropriate stimulus, a 
homogenous increase of BDNF mRNAs is carried out in the cell body, and it can be 
selectively targeted to the active synapse or non-selectively translocated to dendrites, but 
trapped by an active spine, where it would be quickly translated to BDNF protein. Therefore 
BDNF mRNA and BDNF protein may be non-simultaneously stored in different locations 
inside the neurons [61], which would explain the discrepancy between mRNA and protein 
levels found in the present study. We cannot dismiss the idea that in our model, the absence 
of injury in the hippocampus is due to the generation of BDNF in this area [62]. 
In addition to being involved in learning plasticity and neural cell death [63], the 
glutamate/glutamatergic system is involved in addiction to several drugs of abuse [64]; but 
knowledge of glutamate receptor regulation following MDMA administration is limited. 
Kindlundh-Högberg et al. [65] investigated in adolescent rats the immediate effects of 
repeated intermittent MDMA administration upon gene-transcript levels of glutamatergic 
receptors. In contrast to other brain areas, they did not found changes in hippocampal NR1 
or NR2B expression, 10 h after the last injection. In our study, the evaluation of NR2B, PSD-
95 and synaptophysin also yielded constant levels, with only NR1 showing a tendency to 
decrease, which was not statistically significant. 
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Drugs of abuse, such as psychostimulants, usurp the normal basic reward function, 
essentially hijacking molecular and cellular processes, such as those involved in addiction, 
leading to persistent adaptive behavioral responses [64]. It is not completely understood to 
what extent these maladaptive changes in the reward circuit expand and affect other brain 
areas. In the present study, young mice exposed to intermittent and repeated doses of 
MDMA showed increased expression of key early markers of plasticity, which sometimes 
persisted for 3 months. Considering that the neuronal injury was detected in the SN but not in 
the hippocampus, we suggest that hippocampal maladaptive plasticity could explain the 
memory deficits evidenced here.  
 
Conclusions 
Mice exposed to an intermittent and repetitive schedule of MDMA for 8 weeks initially 
showed lower locomotor activity, concordant with the reduction of DA neurons in the SN and 
the depletion of DA in the striatum. Consistent with what happens with DA in the striatum, 3 
months after treatment, this hypolocomotor effect disappeared. Mice also exhibited deficits in 
recognition memory that persisted at least 3 months ATET. However, in the hippocampus, 
MDMA administration did not cause any changes in 5-HT terminals or in NMDA subunits, 
indicating that other mechanisms underlie MDMA-elicited memory deficits. These behavioral 
changes correlate with significant overexpression of hippocampal plasticity markers 
downstream of CREB phosphorylation, which could be the result of DA D1 receptor 
stimulation. It is especially worth stressing the long-lasting increase in BDNF protein after 
drug exposure.  
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FIGURE LEGENDS 
Figures were created using GraphPad Prism program 
Fig. 1: Assessment of recognition memory in animals exposed to saline or MDMA and tested 
one week (A, n=26) or three months (B, n=23) after the end of the treatment. The time spent 
exploring new object was registered 1 h and 24 h after the familiarization session, and 
expressed as measures of discrimination between the new and familiar object. Data are 
presented as mean ± SEM. Two-way ANOVA revealed a significant effect of delay time (2w 
F1,24 = 83.78, P <0.001; 3m: F1,21 = 33.23, P <0.001) and of the interaction treatment x delay 
time (2w: F1,24 = 4.27, P <0.05; 3m: F1,21 = 60.95, P <0.001). Post-hoc comparisons by 
Tukey’s procedure yielded the significances that are displayed in the graph. * P <0.05 vs 
time-matched saline.  
Fig. 2: Exposure to MDMA significantly decreased the TH positive neurons in the SN. Bar 
graph show the number of TH positive neurons in SN, two weeks after the last exposure to 
the drug. Data represent the mean ± SEM. Post-hoc Turkey test: * P<0.05 vs  saline. Panels 
show representative photomicrographs of the effects of Saline or MDMA on TH 
immunofluorescence in the SN, after 2 weeks of withdrawal. Scale bar: 50µM. 
Fig. 3: Long lasting effect of exposure to MDMA on TH positive neurons in the SN. Bar graph 
show the number of TH positive neurons in SN, 3 months after the last exposure to the drug. 
Data represent the mean ± SEM. Post-hoc Turkey test: * P<0.05 vs  saline. show 
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representative photomicrographs of the effects of MDMA on TH immunofluorescence in the 
SN, after 3 months of withdrawal. Scale bar: 50µM. 
Fig. 4: Effect of MDMA exposure on the expression of mouse hippocampal proteins CREB 
(A, C) and p-CREB (B, D). This was assessed two weeks (2w: A, B) or three months (3m: C, 
D) after the end of the treatment. Data are presented as mean ± SEM; * P <0.05 vs saline. 
Fig. 5: Effect of MDMA exposure on the expression of mouse hippocampal c-Fos mRNA 
transcript (A, C) and protein (B, D) tested two weeks (2w) or three months (3m) after the end 
of the treatment (A, B; and C, D, respectively). Data are presented as mean ± SEM; * P 
<0.05 vs saline. 
Fig. 6: Consequences of repeated and intermittent MDMA exposure for mouse hippocampal 
Arc mRNA transcript (A, C) and protein expression (B, D) assessed two weeks (2w: A, B) or 
three months (3m: C, D) after the end of the treatment. Data are presented as mean ± SEM; 
* P <0.05 and **P<0.01 vs saline. 
Fig. 7: Effect of MDMA exposure on mouse hippocampal BDNF mRNA transcript (A, C) and 
protein expression (B, D) tested two weeks (2w) or three months (3m) after the end of the 
treatment (A, B; and C, D, respectively). Data are presented as mean ± SEM; * P <0.05 vs 
saline. 
Fig. 8: Lack of specific regulation of synaptic plasticity-related proteins by repeated and 
intermittent MDMA treatment, in mouse hippocampus. Expression of the: NR1 (A, E), NR2 
(B, F), PSD-95 (C, G) and synaptophysin (D, H) proteins was evaluated two weeks (2w: A, B, 
C, D) or three months (3m: E, F, G, H) after the end of the treatment. Data are presented as 
mean ± SEM. 
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